AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9666830
Drug: 3 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times weekly narrow-band TL-01 UVB phototherapy
Trial: 7648653
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg TID)
Trial: 2667654
Drug: Adjuvant cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant cytotoxic chemotherapy (76 patients)
Trial: 2667654
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic adjuvant treatment (93 patients)
Trial: 2667654
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy (oral cyclophosphamide and intravenous methotrexate and 5‐fluorouracil) for 12 cycles over one year
Trial: 908220
Drug: fenoterol 400
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol 400 μg
Trial: 908220
Drug: fenoterol 200
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol 200 μg
Trial: 908220
Drug: fenoterol 100
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol 100 μg
Trial: 908220
Drug: isoproterenol 150
RxNorm normalized name: anhydrous calcium iodide-isoproterenol 150 mg-3 mg/5 mL oral syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isoproterenol 150 μg
Trial: 908220
Drug: All drug
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drug regimens
Trial: 29728338
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with Magnesium (Mg)
Trial: 29728338
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment with maltose
Trial: 28210090
Drug: Stellate ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate ganglion block treatment (experimental group, n = 90)
Trial: 28210090
Drug: Oral sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulfasalazine treatment (control group, n = 30)
Trial: 18505226
Drug: Clearfil SE
RxNorm normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clearfil SE Bond with 37% phosphoric acid gel
Trial: 18505226
Drug: Xeno III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeno III with 37% phosphoric acid gel
Trial: 11142927
Drug: Formica rufa
RxNorm normalized name: Formica Rufa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formica rufa D6 (1 ml) + autologous blood (0.5 ml)
Trial: 11142927
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 ml NaCl intramuscular)
Trial: 1510000
Drug: Flecainide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (2 mg/kg body weight in 10 minutes)
Trial: 1510000
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg body weight in 10 minutes)
Trial: 1510000
Drug: Verapamil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (10 mg in 1 minute)
Trial: 29776916
Drug: NIR light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR light therapy (940 nm) to acupoints in the legs and feet, 12 sessions during hemodialysis three times a week
Trial: 29776916
Drug: NIR light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR light therapy (940 nm) to acupoints in the legs and feet
Trial: 25640007
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day SCSE for 14 days
Trial: 24285458
Drug: Specialized physiotherapy
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized physiotherapy methods (6 additional massage treatments, 30 minutes each, over a few days)
Trial: 24285458
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard pharmacological treatment and basic physiotherapy)
Trial: 21034249
Drug: Phage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phage treatment (3×10^9 plaque forming units) administered via oral gavage at 24 and 48 hours
Trial: 21034249
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no phage treatment)
Trial: 21034249
Drug: Phage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phage treatment
Trial: 16572330
Drug: 1.0% water-soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% water-soluble reduced chitosan (5.0 g/l)
Trial: 12573306
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV) 2 mg
Trial: 7515260
Drug: Aprotinin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (0.5 x 10(6) KIU intravenous bolus after induction and 10(6) KIU into the pump prime)
Trial: 2885022
Drug: Adimolol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adimolol (600 mg)
Trial: 26204987
Drug: Carraguard microbicide
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carraguard microbicide gel
Trial: 26204987
Drug: High adherence
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High adherence (gel used in >=85% of sex acts)
Trial: 25277886
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein concentrate (WPC) 65 g dissolved in 500 mL water 30 minutes before lunch
Trial: 25277886
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (SPI) 60 g dissolved in 500 mL water 30 minutes before lunch
Trial: 20427390
Drug: LAL: levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAL: levofloxacin (750 mg once a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Trial: 20427390
Drug: CAL: clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL: clarithromycin (500 mg twice a day), amoxicillin (1000 mg twice a day), lansoprazole (30 mg twice a day) for 7 days
Trial: 20427390
Drug: LAL as
RxNorm normalized name: Lathanol LAL
DrugBank: Sodium lauryl sulfoacetate (DB13157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAL as second-line treatment
Trial: 20427390
Drug: CAL as
RxNorm normalized name: Cal Gest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL as second-line treatment
Trial: 26051846
Drug: Phonophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonophoresis with dexketoprofen (50 mg/session) (n=33)
Trial: 26051846
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with dexketoprofen (50 mg/session) (n=34)
Trial: 22554205
Drug: Glycerin 1%
RxNorm normalized name: GLYCERIN 1% OPH SOLN SPRAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin 1% formulated with PLL-g-PEG
Trial: 20404743
Drug: Bedtime dosing
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime dosing of candesartan (with or without diuretic)
Trial: 20404743
Drug: Awakening dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Awakening dosing of candesartan (with or without diuretic)
Trial: 20404743
Drug: Bedtime dosing
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime dosing of candesartan in morning hypertension group
Trial: 20404743
Drug: Awakening dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Awakening dosing of candesartan in morning hypertension group
Trial: 12394700
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg daily for 2 weeks before surgery
Trial: 27104933
Drug: Everolimus combined
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus combined with cyclosporine A (CsA) and steroids
Trial: 17299100
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment program including cognitive behavioral therapy, interpersonal therapy, nutritional counseling, and supervised walking exercise (15 sessions).
Trial: 15805342
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2 and 4 mg)
Trial: 15805342
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch and gum
Trial: 15805342
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (patch, gum, placebo)
Trial: 15805342
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch therapy with cognitive-behavioral therapy
Trial: 30777645
Drug: Intervention (We
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (We Immunize Program with practical strategies training and monthly telephonic expert feedback)
Trial: 26467301
Drug: Chlorhexidine-containing brush-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-containing brush-on gel (0.2% chlorhexidine digluconate) used once daily for 12 weeks
Trial: 16778332
Drug: Imidapril 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril 2.5 mg once daily for 6 months
Trial: 14759425
Drug: Intravenous methylene
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylene blue (1.5 mg/Kg)
Trial: 11718638
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) patch (5 mg for 3 days)
Trial: 2824708
Drug: Late intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late intensification chemotherapy (high-dose chemotherapy)
Trial: 30006361
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of the β‐blocker propranolol
Trial: 30006361
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of amisulpride
Trial: 16160693
Drug: Chemotherapy (beneficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (beneficial effect group, n = 245)
Trial: 16160693
Drug: Chemotherapy (progressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (progressive disease group, n = 58)
Trial: 16160693
Drug: Chemotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (group with 0-1 adverse events)
Trial: 16160693
Drug: Chemotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (group with 2-5 adverse events)
Trial: 16160693
Drug: Chemotherapy (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (group with >=6 adverse events)
Trial: 12831816
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n=199) with lifestyle modification and pharmacological treatments individualized by a geriatrician
Trial: 8880109
Drug: Ultrasonically-nebulized distilled
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonically-nebulized distilled water (UNDW) - 10 min inhalation
Trial: 8880109
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HS) - stepwise inhalation of 4.5% saline for 0.5, 1, 2, 4, and 8 min
Trial: 31100611
Drug: Bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300 mg for 8 weeks)
Trial: 30196397
Drug: MDMA (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (75 to 125 mg)
Trial: 17725245
Drug: DEX 960
RxNorm normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DEX 960 mg
Trial: 17725245
Drug: DEX 1,920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 1,920 mg
Trial: 16038522
Drug: Amoxicillin/sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/sulbactam
Trial: 12048095
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (group I) with continuous infusion of bupivacaine 0.125% and 2mg fentanyl/ml at a dosage of 6-10 ml per hour for 5 days.
Trial: 12048095
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block (group II) with 20 ml 0.5% bupivacaine applied at the end of the operation.
Trial: 7743697
Drug: Vasodilator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator therapy (hydralazine/isosorbide dinitrate)
Trial: 26509639
Drug: Carboxymethylcellulose (CMC)
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose (CMC) gel
Trial: 23047822
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus standard chemotherapy)
Trial: 23047822
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (3 + 7)
Trial: 23047822
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg intravenously at days 1 and 15, plus cytarabine 1000 mg/m(2) twice daily on days 1‐6)
Trial: 17304449
Drug: Sb(v) plus
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sb(v) plus oral pentoxifylline for 30 days
Trial: 17304449
Drug: Sb(v) plus
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sb(v) plus oral placebo
Trial: 3281387
Drug: Adjuvant-only preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant-only preparation
Trial: 5317541
Drug: Metaproterenol aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol aerosol (0.65 mg per dose, taken as required several times daily)
Trial: 5317541
Drug: Metaproterenol aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol aerosol (average treatment duration of about four months)
Trial: 5317541
Drug: Metaproterenol oral
RxNorm normalized name: metaproterenol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol oral tablets (20 to 80 mg daily for an average of about three weeks)
Trial: 26152418
Drug: Emodepside/Praziquantel solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emodepside/Praziquantel solution (3 mg/kg emodepside and 12 mg/kg praziquantel)
Trial: 3485398
Drug: Intranasal nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal nifedipine
Trial: 30412065
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy with esomeprazole 40 mg
Trial: 30412065
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with esomeprazole 20 mg
Trial: 19919569
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg/day combined with peginterferon (Peg‐IFN)‐alpha‐2b/ribavirin (RBV) for 48 weeks
Trial: 18990058
Drug: Adenovirus type
RxNorm normalized name: Adenovirus types 4 and 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 monovalent gag and trivalent gag/pol/nef vaccines
Trial: 18990058
Drug: Adenovirus type
RxNorm normalized name: Adenovirus types 4 and 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines with >or=1 x 10(10) gag‐containing Ad5 particles per dose
Trial: 18990058
Drug: Adenovirus type
RxNorm normalized name: Adenovirus types 4 and 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus type 5 (Ad5)‐vectored clade B HIV‐1 vaccines
Trial: 19675365
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol dose
Trial: 11051345
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Trial: 11051345
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Trial: 11051345
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg b.i.d.) for 2 weeks followed by clarithromycin (250 mg b.i.d.) and metronidazole (500 mg b.i.d.) for 1 week
Trial: 3979000
Drug: Dazoxiben (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dazoxiben (100 mg, intravenously every 4 hours for a maximum of 72 hours)
Trial: 24720918
Drug: Sitaxsentan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan 100 mg/day
Trial: 22578518
Drug: Anthracycline chemotherapy
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline chemotherapy (mean dose, 296 ± 103 mg/m²)
Trial: 20880151
Drug: Propofol loading
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol loading dose administered over 3.0 min (4 mg·kg(‐1))
Trial: 20880151
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 200 mcg·kg(‐1)·min(‐1) for 5 min or until respiratory insufficiency observed
Trial: 11322207
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU of interferon (IFN) tiw plus ribavirin (1000‐1200 mg/daily) for 12 months
Trial: 11322207
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU of interferon (IFN) tiw monotherapy
Trial: 9130939
Drug: Hib polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP)
Trial: 8433727
Drug: Thrombolytic agent
RxNorm normalized name: Thrombolytic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agent (tissue plasminogen activator)
Trial: 8433727
Drug: Immediate angioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate angioplasty and thrombolytic agent
Trial: 3314973
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg, 5 times a day for 5 days
Trial: 3314973
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg and Placebo
Trial: 23937975
Drug: Stepped-care programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care programme (watchful waiting, guided self-help, problem solving treatment, referral to general practitioner)
Trial: 20562124
Drug: Azithromycin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (n = 40), administered three times a week for 2 years
Trial: 16507189
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction with sevoflurane followed by subhypnotic dose of propofol (1 mg kg‐1)
Trial: 16507189
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol induction
Trial: 11055098
Drug: Zinc nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc nasal gel (Zicam)
Trial: 8927940
Drug: Modified-release amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release amoxicillin tablet
Trial: 28931127
Drug: 1 standard
RxNorm normalized name: Kroger Universal 1 Standard Lancet 21G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 standard dose IM dose of PVRV
Trial: 28931127
Drug: 1/5th‐fractional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/5th‐fractional dose ID of PVRV
Trial: 28931127
Drug: 2/5th‐fractional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2/5th‐fractional dose ID of PVRV
Trial: 28931127
Drug: 3/5th‐fractional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3/5th‐fractional dose ID of PVRV